Login to Your Account

Genmab Licenses HuMax-CD20 To GSK In Potential $2.1B Deal

By Cormac Sheridan

Wednesday, December 20, 2006
Billing it as the biotechnology industry's biggest ever drug deal, Genmab A/S licensed the human monoclonal antibody HuMax-CD20 (ofatumumab) to GlaxoSmithKline plc in a transaction with a total potential value exceeding DKK12 billion (US$2.1 billion) and a guaranteed amount of about DKK2.6 billion. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription